psalexa
logo

Proteasome Inhibitors Therapeutics Pipeline, 2017

Proteasome Inhibitors Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: October 2017
Report Code: LS11327
Available Format:
Pages: 89

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Proteasome Inhibitor Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Proteasome Inhibitor Therapeutics Pipeline Analysis by Phase (2017)

5.1 Phase II: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase I: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Pre-Clinical: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Strategic Development

5.3.4 Designation

5.3.5 Grants

5.3.6 Patent

5.3.7 Technology

5.4 Discovery: Drug profiles

5.4.1 Strategic Development

5.4.2 Designation

5.4.3 Grants

5.4.4 Patent

5.4.5 Technology

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials, by Region

6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Proteasome Inhibitor Therapeutics Pipeline

7.2 SWOT Analysis of Proteasome Inhibitor Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

PIPELINE ANALYSIS OF PROTEASOME INHIBITOR BY COMPANY (2017)

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

COMPANIES – AT A GLANCE

 

LIST OF FIGURES

 

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

NUMBER OF PROTEASOME INHIBITOR DRUG CANDIDATES UNDER DEVELOPMENT (2017)

PROTEASOME INHIBITOR PIPELINE SPLIT, BY MOLECULE TYPE (2017)

PROTEASOME INHIBITOR PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING

SWOT ANALYSIS 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry